Success Story: Graduate Student Researcher from Iran Secures NIW Approval with Our Support

Client’s Testimonial:

“I am thrilled to share my deep appreciation for the exceptional support I received during my EB2/NIW application process. The legal team was remarkably attentive, promptly addressing all my inquiries with clarity and precision. Their expertise made the entire process much smoother and more efficient. The constructive feedback provided during the drafting of my petition letter was particularly valuable, ensuring everything was on point.

I also want to highlight the comprehensive templates and guidance materials they provided. As someone unfamiliar with the NIW process, these resources were a game-changer. They offered clear insights into the required documentation and steps, significantly easing my stress and helping me stay organized from the very beginning.”

On February 6^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student Researcher in the Field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Case Filing: Graduate Student Researcher

Country of Origin: Iran

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: February 6^th, 2025

Processing Time: 9 months, 22 days

Case Summary:

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a biomedical science researcher with an M.S. in human genetics. At the time of filing, the client was engaged in advanced scientific work and had already developed a strong record of research contributions in genetics and disease modeling.

Research Focus and Contributions:
The client’s proposed endeavor is to advance integrative deep learning and multi-omics frameworks to study the genetic and molecular determinants of white matter pathology. This research has significant implications for Alzheimer’s disease and related conditions, with the potential to inform the development of more effective and targeted therapies. By combining computational biology, genetics, and biomedical sciences, the client is addressing one of the most pressing healthcare challenges of our time.

Research Impact and Achievements:
To demonstrate the client’s influence and national importance, our petition emphasized several key metrics:

Publications: 13 peer-reviewed journal articles, including 2 first-authored and 2 co-first-authored works
Citations: 137 citations on Google Scholar, showing the client’s work is widely referenced in the field
Peer Review Service: At least 3 reviews completed for respected scientific journals, reflecting recognition of the client’s expertise

Well Positioned to Advance the Proposed Endeavor:
We demonstrated that the client’s training in human genetics, combined with his innovative application of deep learning and multi-omics analysis, uniquely positioned him to continue making impactful discoveries. His prior work provided a strong foundation for the ongoing development of predictive models that could revolutionize the way genetic and molecular insights are translated into clinical therapies.

NIW Approval and Outlook:
Approved in February 2025, the NIW petition was granted in recognition of the client’s significant achievements and potential to contribute to U.S. national interests through biomedical innovation. NAILG is proud to have successfully represented this client and looks forward to seeing the continued impact of his research in advancing treatments for neurological diseases.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.